Is Cosentyx Safe While Breastfeeding?
No clear evidence shows Cosentyx (secukinumab) harms breastfed infants, but data is limited, and experts recommend caution.[1] The drug, an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, passes into breast milk in small amounts. A 2023 study detected secukinumab in the milk of five breastfeeding mothers at low levels (0.001-0.005% of the maternal dose), with no accumulation in infants.[2] Infant exposure remains minimal due to poor oral absorption of biologics like IgG1 antibodies.
What Do Medical Guidelines Say?
The American Academy of Pediatrics and LactMed database classify Cosentyx as compatible with breastfeeding, citing negligible risk from low milk transfer and digestion in the infant gut.[1][3] Novartis, the manufacturer, states no data on effects in exposed infants but notes potential for hypersensitivity reactions; they advise weighing benefits against risks.[4] Rheumatology societies often endorse continuing treatment if maternal disease control is critical, as uncontrolled inflammation poses greater risks to mother and baby.
How Much Cosentyx Gets into Breast Milk?
Peak milk concentrations occur 5-7 days post-dose, but levels drop quickly (half-life ~3 days in milk).[2] Estimated infant dose via breastfeeding is under 1% of the therapeutic maternal dose, far below amounts causing effects in animal studies.[1] Pumping and discarding milk for 4-6 half-lives (12-18 days) after the last dose ensures near-zero exposure, though this disrupts supply and is rarely needed.[3]
What Risks Do Infants Face?
Reported adverse events in exposed infants are absent in published data, but monitor for infections or allergic reactions due to Cosentyx's immunomodulating effects.[4] No long-term studies exist on neurodevelopment or immunity. Premature or immunocompromised infants may warrant extra caution.
Can You Take It During Pregnancy Too?
Cosentyx shows no increased malformation risk in pregnancy registries (over 900 exposures), with transfer across the placenta highest in the third trimester.[5] Breastfeeding safety aligns with this profile, but consult a doctor for personalized timing.
What Do Doctors Recommend as Alternatives?
If stopping Cosentyx, consider topicals or shorter-acting drugs like methotrexate (not for breastfeeding).[6] Biologics like adalimumab or etanercept have similar low-transfer profiles.[3] Discuss with an obstetrician, rheumatologist, or lactation consultant—maternal health often trumps minor infant risks.
[1]: LactMed - Secukinumab
[2]: JAMA Dermatology study on secukinumab in breast milk (2023)
[3]: American Academy of Pediatrics breastfeeding guidelines
[4]: Cosentyx Prescribing Information (Novartis)
[5]: Cosentyx Pregnancy Exposure Registry
[6]: ACR guidelines on rheumatic disease in pregnancy/breastfeeding